Default Category
-
Guangzhou Kingmed Diagnostics: Post-IPO Transformation
Brian Hwarng, Xuchuan YuanCase IVEY-W25196-EService and Operations Management, StrategyGuangzhou KingMed Diagnostics was the leading third-party independent clinical laboratory in China. On the eve of the Lunar New Year in 2020, the chairman and CEO of Guangzhou KingMed Diagnostics mobilized the whole group to respond to the outbreak of the new coronavirus from Wuhan. With the group’s tremendous growth in both business and size since its initial public offering, there were growing concerns about the provision of quality customer se...Starting at €8.20